Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) that came out of Ivan Ashmarin's group at the Institute of Molecular Genetics, Russian Academy of Sciences, in the late 1980s (Ashmarin et al., Neurosci Behav Physiol, 1997). It's a synthetic analogue of the ACTH(4-10) fragment — the part of adrenocorticotropic hormone that drives cognitive and neuroprotective effects — with a Pro-Gly-Pro tail tacked onto the C-terminus. That tail is the whole trick: it makes the molecule far more resistant to proteolytic chew-up and stretches functional half-life. Semax has been a registered drug in Russia since 1999, used clinically for stroke recovery, cognitive impairment, and neuroprotection (Medvedeva et al., Front Pharmacol, 2014).
Key Takeaways
- —Semax is ACTH(4-10)-Pro-Gly-Pro, a synthetic heptapeptide registered as a drug in Russia for stroke and cognitive impairment since 1999. There's no equivalent Western regulatory approval.
- —Semax upregulates BDNF (brain-derived neurotrophic factor) and NGF in the hippocampus within 1 hour of administration in rat models — the fastest BDNF upregulation mechanism of any known peptide (Dolotov et al., J Neurochem, 2006).
- —Unlike ACTH itself, Semax produces no HPA axis activation. It doesn't bump cortisol, ACTH, or adrenal hormones at therapeutic doses, because it lacks the N-terminal sequence that drives steroidogenesis.
- —Administered intranasally: bypasses the blood-brain barrier via olfactory ensheathing cells, so you get CNS delivery without a needle.
Full-length ACTH (39 amino acids) does two very different jobs. The N-terminal sequence (ACTH 1-17) hits the adrenal cortex and triggers cortisol release. The mid-chain fragment (ACTH 4-10: Met-Glu-His-Phe-Pro-Gly) is the cognitive and neuroprotective piece, working through melanocortin receptors (MC4R) in the CNS and via neurotrophin upregulation that's independent of the hormonal arm.
Semax keeps the ACTH 4-10 sequence but deliberately drops the steroidogenic N-terminus. The Pro-Gly-Pro extension added by Zakharova and Myasoedov's team buys two things: real resistance to dipeptidyl peptidase and other CNS proteases, and better CNS penetration via the intranasal route. End result — you get ACTH's cognitive effects without ACTH's hormonal baggage.
The fact that Semax doesn't activate the HPA axis isn't a happy accident — it's the whole design objective. ACTH 4-10 was known to improve learning and memory in animal models going back to De Wied's work in Utrecht in the 1970s, but it was unusable as a therapeutic because parent ACTH cranked cortisol. Semax fixed that structurally, not pharmacologically. It's a clean example of rational peptide engineering producing a clinically usable compound out of basic research.
BDNF and NGF upregulation: This is the headline finding in the mechanistic literature. Intranasal Semax in rats rapidly elevated BDNF and trkB expression in the hippocampus and frontal cortex within 1 hour of administration, working through MAP kinase pathway activation (Dolotov et al., J Neurochem, 2006). NGF went up the same way. BDNF is the principal mediator of synaptic plasticity, neurogenesis, and long-term potentiation — the molecular substrate of learning and memory consolidation.
Melanocortin receptor activation (MC4R): Semax binds melanocortin receptors in the prefrontal cortex and limbic system, lighting up cAMP signalling pathways tied to attention, working memory, and cognitive flexibility.
Neuroprotection via oxidative stress mitigation: In ischaemia models, Semax cuts glutamate excitotoxicity, blunts oxidative damage, and bumps antioxidant gene expression. That's the mechanism behind its stroke recovery use.
Dopamine, serotonin and opioid system modulation: Semax raises dopamine turnover in mesocortical pathways without the tolerance, dependence, or receptor downregulation you get with direct dopamine agonists. Serotonin synthesis genes also go up in hippocampal tissue, and Semax tweaks enkephalin degradation and endogenous opioid signalling, which feeds into its anti-stress profile (Eremin et al., Int J Biochem Cell Biol, 2005).
Intranasal Semax produced a 140% increase in BDNF mRNA expression in the hippocampus within 1 hour of administration in rat models, making it the fastest-acting BDNF upregulator of any studied compound (Dolotov et al., Journal of Neurochemistry, 2006). A BDNF jump that size is comparable to 4-6 weeks of aerobic exercise — pulled off in a single acute dose, with the obvious caveat that animal-to-human extrapolation needs independent validation.
Semax's clinical evidence base is mostly from Russian trials, which are harder to access and harder to evaluate than Western data. The strongest published findings:
Stroke and cerebrovascular disease: Multiple Russian clinical trials report better neurological outcome scores, faster functional recovery, and less cognitive deficit at 30-day follow-up in ischaemic stroke patients given Semax (6-12 mcg/kg/day intranasal) versus standard care (Gusev et al., Neurosci Behav Physiol, 2005). Semax is also approved in Russia for cerebrovascular insufficiency and cognitive decline, as documented in the Medvedeva pharmacology review (Medvedeva et al., Front Pharmacol, 2014).
Optic nerve disease: A published RCT in patients with optic nerve disease (glaucomatous neuropathy) showed Semax improved visual acuity and visual field measures versus placebo. That one's among the more methodologically solid Semax trials.
Cognitive function in healthy subjects: Smaller studies in healthy volunteers and operators under high cognitive load report gains in sustained attention, working memory recall, and processing speed after intranasal Semax (Kaplan et al., Neurosci Behav Physiol, 1996). Sample sizes are small (N=20-60) and there's no long-term follow-up data.
The honest limitation: Semax's clinical evidence base hasn't been replicated in large prospective RCTs run under Western GCP. The compound is registered as a drug in Russia — meaning it cleared Russian regulatory standards — but it's not in the EMA or FDA databases.
Semax's most distinctive feature on the practical side is intranasal delivery. The olfactory epithelium gives you direct CNS access via olfactory ensheathing cells, skipping the blood-brain barrier. This isn't a theoretical claim — the nasal route is what's used in the registered Russian pharmaceutical product and in basically all the published clinical research.
| Parameter | Protocol |
|---|---|
| Route | Intranasal (primary) — SC injection also used in some protocols |
| Dose | 200-600 mcg/day intranasal (typical research protocol) |
| Frequency | Once or twice daily |
| Concentration | Available as 0.1% (100 mcg/drop) or 1% (1000 mcg/drop) nasal solution |
| Timing | Morning administration preferred (aligns with natural BDNF synthesis peaks) |
| Cycle | 2-4 weeks on, 2 weeks off |
Practical note: The registered Russian product (made by Peptide Technologies, Moscow) ships as a pre-mixed nasal solution. Research-grade Semax is usually lyo powder you reconstitute in BAC water or saline, then run through a nasal spray bottle (atomised so it actually coats the mucosa evenly).
Semax has been in clinical use in Russia since 1999 — that's a post-market safety record over 25 years deep. No serious adverse events have been pinned on Semax at clinical doses in any published series. Notable safety characteristics:
Semax has been registered as a pharmaceutical in the Russian Federation since 1999 and has been in continuous clinical use for over 25 years. Published adverse event data and post-market pharmacovigilance in Russian clinical settings haven't surfaced serious safety signals. Its lack of HPA axis activation is what separates it from ACTH itself and rules out the hypothalamic-pituitary-adrenal side effect profile as a concern at therapeutic doses.
Semax sits in a regulatory grey zone that most vendor sites gloss over — and the BDNF/ACTH mechanism data deserves more scrutiny than product listings usually give it. The Next Pep peptide library covers the full heptapeptide profile: the ACTH(4-10)-Pro-Gly-Pro structure, BDNF upregulation mechanism, Russian pharmaceutical status, intranasal pharmacokinetics, and the stroke recovery versus cognitive enhancement evidence — all cross-referenced against primary sources.
Use the comparison tool to put Semax next to Selank or other nootropic peptides side-by-side, comparing mechanisms, evidence quality, and delivery routes. For injectable or intranasal protocols, the dosing calculator handles the reco math: enter your vial concentration and target dose and it returns exact volume.
Both are Russian-developed intranasal peptides registered as pharmaceuticals in Russia. Semax (ACTH analogue) is mainly cognitive-enhancing and neuroprotective via BDNF/NGF upregulation and melanocortin activation. Selank (Tuftsin analogue) is mainly anxiolytic via GABA modulation and enkephalin degradation inhibition. Different receptor systems, often stacked: Semax for focus and cognitive performance, Selank for anxiety and stress resilience. They don't overlap mechanistically.
Semax isn't scheduled and isn't FDA-approved. In the US it sits in a legal grey area: not a controlled substance, but buying it as a drug for human use isn't authorised. Research-grade Semax is sold by peptide suppliers for in-vitro research use. The regulatory situation lines up with most unapproved research peptides.
BDNF upregulation in animal models hits within 1 hour of intranasal administration. Human studies on cognitive performance don't pin down precise onset, but anecdotally people consistently describe effects within 15-45 minutes of nasal dosing — consistent with the rapid CNS delivery mechanism. Duration is typically 4-8 hours, subjective.
Semax's mechanisms — BDNF upregulation, dopamine turnover increase, sustained attention improvement — are mechanistically relevant to ADHD. Some published Russian data included people with attention disorders. There are no randomised controlled trials specifically in ADHD-diagnosed patients meeting Western diagnostic criteria, though, so this remains an off-label extrapolation.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.